1. Methodologies for in vitro and in vivo evaluation of efficacy of antifungal and antibiofilm agents and surface coatings against fungal biofilms
- Author
-
Elizabeth M. Johnson, Mahmoud A. Ghannoum, Michael R. Yeaman, Carol A. Munro, Patrick Van Dijck, Jeniel E. Nett, Dominique Sanglard, Richard Calderone, Leah E. Cowen, Johan Maertens, Maiken Cavling Arendrup, Axel A. Brakhage, Judith Berman, Katrien Lagrou, Christophe d'Enfert, Karin Thevissen, Paul Cos, Gordon Ramage, Jelmer Sjollema, Tom Coenye, Isabel Spriet, Paul E. Verweij, Jose L. Lopez-Ribot, Ana Espinel-Ingroff, Sebastian A. J. Zaat, Emilia Cantón, Mary Ann Jabra-Rizk, David R. Andes, Neil A. R. Gow, Scott G. Filler, Mira Edgerton, Maurizio Sanguinetti, Michael A. Pfaller, Joost Wauters, Bruno P. A. Cammue, Clarissa J. Nobile, Hubertus Haas, Adilia Warris, Shawn R. Lockhart, Van Dijck, Patrick, Sjollema, Jelmer, Thevissen, Karin, Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), University Medical Center Groningen [Groningen] (UMCG), Vlaams Instituut voor Biotechnologie [Ghent, Belgique] (VIB), Center for Plant Systems Biology (PSB Center), Tel Aviv University [Tel Aviv], Biologie et Pathogénicité fongiques, Institut Pasteur [Paris]-Institut National de la Recherche Agronomique (INRA), University of Wisconsin-Madison, Statens Serum Institut [Copenhagen], Rigshospitalet [Copenhagen], Copenhagen University Hospital, University of Copenhagen = Københavns Universitet (KU), Leibniz Institute for Natural Product Research and Infection Biology (Hans Knoell Institute), Friedrich-Schiller-Universität = Friedrich Schiller University Jena [Jena, Germany], Georgetown University Medical Center, Medical Research Institute La Fe, Partenaires INRAE, Universiteit Gent = Ghent University [Belgium] (UGENT), ESCMID [Basel], University of Antwerp (UA), University of Toronto, University at Buffalo [SUNY] (SUNY Buffalo), State University of New York (SUNY), Virginia Commonwealth University (VCU), Harbor UCLA Medical Center [Torrance, Ca.], University Hospitals of Cleveland, Case Western Reserve University [Cleveland], University of Aberdeen, Innsbruck Medical University [Austria] (IMU), University of Maryland [Baltimore], Public Health England, Centers for Disease Control and Prevention [Atlanta] (CDC), Centers for Disease Control and Prevention, The University of Texas at San Antonio (UTSA), UZ Leuven, University of California [Merced], University of California, University of Iowa [Iowa City], JMI Laboratories, University of Glasgow, Université de Lausanne (UNIL), Centre Hospitalier Universitaire Vaudois [Lausanne] (CHUV), Università cattolica del Sacro Cuore [Roma] (Unicatt), Radboud university [Nijmegen], Univ Aberdeen, Aberdeen Fungal Grp, MRC Ctr Med Mycol, Foresterhill, Aberdeen, Scotland, University Hospitals Leuven [Leuven], Academic Medical Center - Academisch Medisch Centrum [Amsterdam] (AMC), University of Amsterdam [Amsterdam] (UvA), Industrial Research Fund [IOFm/05/022], Israel Science Foundation [314/13], Wellcome Trust, MRC, Agence Nationale de Recherche [ANR-10-LABX-62-IBEID], National Institutes of Health [R35GM124594, R21AI125801], Wellcome Trust Strategic Award [097377], MRC Centre for Medical Mycology at the University of Aberdeen [MR/N006364/1], Astellas, Basilea, Gilead, MSD, NovaBiotics, Pfizer, T2Biosystems, F2G, Cidara, Amplyx, MRC [MR/N006364/1], FWO [FWO WO.009.16N]., ANR-10-LABX-0062,IBEID,Integrative Biology of Emerging Infectious Diseases(2010), European Project: 340087,EC:FP7:ERC,ERC-2013-ADG,RAPLODAPT(2014), Tel Aviv University (TAU), Biologie et Pathogénicité fongiques (BPF), Institut National de la Recherche Agronomique (INRA)-Institut Pasteur [Paris] (IP), University of Copenhagen = Københavns Universitet (UCPH), Universiteit Gent = Ghent University (UGENT), Innsbruck Medical University = Medizinische Universität Innsbruck (IMU), Universitair Ziekenhuis Leuven (UZ Leuven), University of California [Merced] (UC Merced), University of California (UC), Université de Lausanne = University of Lausanne (UNIL), Università cattolica del Sacro Cuore = Catholic University of the Sacred Heart [Roma] (Unicatt), and Radboud University [Nijmegen]
- Subjects
0301 basic medicine ,diagnosis ,[SDV]Life Sciences [q-bio] ,LIPOSOMAL ,lnfectious Diseases and Global Health Radboud Institute for Molecular Life Sciences [Radboudumc 4] ,Applied Microbiology and Biotechnology ,immune response ,biofilm ,High morbidity ,transcriptomics ,MINIMUM FUNGICIDAL ,CONCENTRATIONS ,Amphotericin B ,eradication ,Medicine ,GUINEA-PIG MODEL ,LIPOSOMAL AMPHOTERICIN-B ,lcsh:QH301-705.5 ,AMPHOTERICIN-B ,antibiofilm material coating, antifungal susceptibility testing, biofilm eradication, biofilm inhibition, in vivo models ,antifungal susceptibility testing ,biofilm inhibition ,biofilm eradication ,antibiofilm material coating ,in vivo models ,3. Good health ,CANDIDA-ALBICANS BIOFILMS ,GALLERIA-MELLONELLA ,Infectious Diseases ,tuberculosis ,5.1 Pharmaceuticals ,HUMAN-PATHOGENIC FUNGI ,Development of treatments and therapeutic interventions ,Infection ,Fungal biofilm ,Life Sciences & Biomedicine ,VULVO-VAGINAL CANDIDIASIS ,medicine.drug ,Antifungal ,latent infection ,Medical mycology ,medicine.drug_class ,OXYSPORUM SPECIES COMPLEX ,030106 microbiology ,INVASIVE PULMONARY ASPERGILLOSIS ,Biochemistry, Genetics and Molecular Biology (miscellaneous) ,Microbiology ,GALLERIA-MELLONELLA LARVAE ,03 medical and health sciences ,proteomics ,In vivo ,Virology ,Genetics ,Molecular Biology ,Biology ,Science & Technology ,business.industry ,LARVAE ,Biofilm ,Biology and Life Sciences ,Cell Biology ,In vitro ,Emerging Infectious Diseases ,Good Health and Well Being ,lcsh:Biology (General) ,point-of-care ,Parasitology ,MINIMUM FUNGICIDAL CONCENTRATIONS ,Human medicine ,Antimicrobial Resistance ,RAT SUBCUTANEOUS MODEL ,business - Abstract
Contains fulltext : 196638.pdf (Publisher’s version ) (Open Access) Unlike superficial fungal infections of the skin and nails, which are the most common fungal diseases in humans, invasive fungal infections carry high morbidity and mortality, particularly those associated with biofilm formation on indwelling medical devices. Therapeutic management of these complex diseases is often complicated by the rise in resistance to the commonly used antifungal agents. Therefore, the availability of accurate susceptibility testing methods for determining antifungal resistance, as well as discovery of novel antifungal and antibiofilm agents, are key priorities in medical mycology research. To direct advancements in this field, here we present an overview of the methods currently available for determining (i) the susceptibility or resistance of fungal isolates or biofilms to antifungal or antibiofilm compounds and compound combinations; (ii) the in vivo efficacy of antifungal and antibiofilm compounds and compound combinations; and (iii) the in vitro and in vivo performance of anti-infective coatings and materials to prevent fungal biofilm-based infections.
- Published
- 2018
- Full Text
- View/download PDF